Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
Novo Nordisk raised its 2026 outlook after reporting growth in GLP-1 sales and continued uptake of its oral Wegovy product.
TL;DR
- Novo Nordisk reported third-quarter adjusted operating profit of DKK 31,720 million, up 27% at constant exchange rates, and raised its 2026 outlook.
- The company said Wegovy pill sales reached DKK 5,394 million in the quarter after launches in four markets.
- Reuters reported that the pill beat sales forecasts; the company’s results do not establish future demand or comparative clinical outcomes.
Novo Nordisk said third-quarter adjusted operating profit rose 27% at constant exchange rates to DKK 31,720 million, while reported operating profit fell 9% at constant exchange rates. The company raised its full-year adjusted sales and operating-profit growth outlook to a range of -2% to +2%. [1]
The company reported that Wegovy pill sales reached DKK 5,394 million in the quarter after launches in the US, UAE, UK and Germany. Reuters separately reported that pill sales beat third-quarter forecasts as the company competed with Eli Lilly. [1] [2]
Novo attributed the stronger outlook to GLP-1 sales growth and said its obesity portfolio drove growth. These are company-reported financial results and management explanations, not evidence that the product will maintain its sales pace. [1] [2]
The reports establish commercial uptake during the quarter and a revised corporate outlook. Future demand, the effect of market competition and the durability of the trend remain uncertain; this story makes no treatment recommendation. [1] [2]
Why it matters
The results put oral GLP-1 uptake and its contribution to a major drugmaker’s sales into a measurable commercial frame. The next periods will show whether the early launch performance and improved outlook persist.
Editor's note
Commercial and company-reported information only; no treatment advice.